BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11410415)

  • 1. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
    Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
    Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
    Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
    Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
    Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
    Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM; Morelli VM; Matos MF; Lourenço DM
    Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in the TAFI gene and the risk of venous thrombosis.
    Kostka H; Kuhlisch E; Schellong S; Siegert G
    Clin Lab; 2003; 49(11-12):645-7. PubMed ID: 14651335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
    Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
    Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
    Folkeringa N; Coppens M; Veeger NJ; Bom VJ; Middeldorp S; Hamulyak K; Prins MH; Büller HR; van der Meer J
    Thromb Haemost; 2008 Jul; 100(1):38-44. PubMed ID: 18612536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the protein C gene as risk factor for venous thrombosis.
    Pomp ER; Doggen CJ; Vos HL; Reitsma PH; Rosendaal FR
    Thromb Haemost; 2009 Jan; 101(1):62-7. PubMed ID: 19132190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
    Pruner I; Djordjevic V; Miljic P; Kovac M; Antonijevic N; Rakicevic L; Radojkovic D
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers.
    Morange PE; Aillaud MF; Nicaud V; Henry M; Juhan-Vague I
    Thromb Haemost; 2001 Dec; 86(6):1583-4. PubMed ID: 11776333
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis.
    de Visser MC; Poort SR; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2001 Jun; 85(6):1011-7. PubMed ID: 11434677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation.
    Procare-GEHT Group
    Br J Haematol; 2006 Dec; 135(5):697-702. PubMed ID: 17107352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
    Masini S; Ticconi C; Gravina P; Tomassini M; Pietropolli A; Forte V; Federici G; Piccione E; Bernardini S
    Fertil Steril; 2009 Aug; 92(2):694-702. PubMed ID: 18774564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis.
    Franco RF; Reitsma PH; Lourenço D; Maffei FH; Morelli V; Tavella MH; Araújo AG; Piccinato CE; Zago MA
    Thromb Haemost; 1999 May; 81(5):676-9. PubMed ID: 10365735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY).
    Pieroni F; Lourenço DM; Morelli VM; Maffei FH; Zago MA; Franco RF
    Thromb Res; 2007; 120(2):221-9. PubMed ID: 17113632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.